Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats

被引:16
作者
Doggrell, SA
Wanstall, JC
Gambino, A
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Cardiovasc Pharmacol Grp, Auckland 1, New Zealand
[2] Univ Queensland, Dept Physiol & Pharmacol, Pulm Pharmacol Grp, St Lucia, Qld, Australia
基金
英国医学研究理事会;
关键词
pulmonary hypertension; 4-AP; K-v; 5-HT; ET-1;
D O I
10.1007/s002109900064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of the outward rectifying potassium channel blocker, 4-aminopyridine, on contractile tone and on contractile responses to the spasmogens, 5-hydroxy-tryptamine and endothelin-l, were examined in pulmonary arteries (main and intralobar) and systemic vessels (aorta and mesenteric artery) from rats with and without hypoxic pulmonary hypertension. Hypoxic pulmonary hypertension was induced by exposure of rats to 10% oxygen for 1 week. The development of pulmonary hypertension was associated with (i) depolarization of the cell membrane in intralobar pulmonary artery, but not aorta, and (ii) an increase in sensitivity to 5-hydroxytryptamine in pulmonary, but not systemic, vessels; sensitivity to endothelin-l was unchanged. 4-Aminopyridine contracted all of the vessels studied. In pulmonary hypertension the sensitivity to 4-aminopyridine was increased ten-fold in pulmonary vessels but was unchanged in systemic vessels. Threshold concentrations of 4-aminopyridine (less than or equal to 3 x 10(-3) M) augmented contractions to 5-hydroxytryptamine in main pulmonary artery and aorta from control rats but failed to augment contractions to 5-hydroxytryptamine in main pulmonary artery from pulmonary hypertensive rats. Responses to endothelin-l were not augmented by 4-aminopyridine. The membrane depolarization and the increases in sensitivity to 4-aminopyridine and 5-hydroxytryptamine seen in pulmonary hypertension are compatible with the concept that potassium channel function is altered in pulmonary, but not systemic, vessels from pulmonary hypertensive rats. Our data suggest that in main pulmonary artery a common mechanism is responsible for (i) the augmentation of 5-hydroxytryptamine responses by 4-aminopyridine in control rats, and (ii) the sensitization to 5-hydroxytryptamine seen in pulmonary hypertensive, compared with control, rats in the absence of 4-aminopyridine. Hence, we conclude that the sensitization to 5-hydroxytryptamine may be due to downregulation of 4-aminopyridine-sensitive potassium channels.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 27 条
[1]   Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia [J].
Archer, SL ;
Huang, JMC ;
Reeve, HL ;
Hampl, V ;
Tolarova, S ;
Michelakis, E ;
Weir, EK .
CIRCULATION RESEARCH, 1996, 78 (03) :431-442
[2]   Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels [J].
Barman, SA .
JOURNAL OF APPLIED PHYSIOLOGY, 1997, 83 (02) :569-574
[3]   REGULATION OF ARTERIAL TONE BY ACTIVATION OF CALCIUM-DEPENDENT POTASSIUM CHANNELS [J].
BRAYDEN, JE ;
NELSON, MT .
SCIENCE, 1992, 256 (5056) :532-535
[4]   Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat [J].
Criddle, DN ;
deMoura, RS ;
Greenwood, IA ;
Large, WA .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (05) :813-818
[5]   HYPERPOLARIZING ACTION OF CROMAKALIM ON THE RAT AORTA [J].
DOGGRELL, SA ;
SMITH, JW ;
DOWNING, OA ;
WILSON, KA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 174 (01) :131-133
[6]  
DOGGRELL SA, 1998, IN PRESS P ASCEPT
[7]   Properties of a novel K+ current that is active at resting potential in rabbit pulmonary artery smooth muscle cells [J].
Evans, AM ;
Osipenko, ON ;
Gurney, AM .
JOURNAL OF PHYSIOLOGY-LONDON, 1996, 496 (02) :407-420
[8]   THE ROLE OF MEMBRANE DEPOLARIZATION IN THE CONTRACTILE RESPONSE OF THE RABBIT BASILAR ARTERY TO 5-HYDROXYTRYPTAMINE [J].
GARLAND, CJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1987, 392 :333-348
[9]  
GARLAND GJ, 1985, J PHARMACOL EXP THER, V233, P158
[10]  
HELBIG H, 1992, INVEST OPHTH VIS SCI, V33, P2105